Die meistzitierten Artikel
|
Rang |
Autoren |
Paper |
Zitierungen |
1 | Scher, HI;...; Miller, K;...; de Bono, JS | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy NEW ENGL J MED 367(13): 1187-97 (27 SEP 2012) | 2.574 |
2 | Rosenberg, JE;...; Retz, MM;...; Dreicer, R | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial LANCET 387(10031): 1909-20 (7 MAY 2016) | 1.724 |
3 | Ryan, CJ;...; Suttmann, H;...; Rathkopf, DE | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy NEW ENGL J MED 368(2): 138-48 (10 JAN 2013) | 1.669 |
4 | Parker, C;...; Wedel, S;...; Sartor, O | Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer NEW ENGL J MED 369(3): 213-23 (18 JUL 2013) | 1.624 |
5 | Beer, TM;...; Miller, K;...; Tombal, B | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy NEW ENGL J MED 371(5): 424-33 (31 JUL 2014) | 1.452 |
6 | Abeshouse, A;...; [+311 Koautoren, darunter Graefen, M; Sauter, G; Schlomm, T; Simon, R] | The Molecular Taxonomy of Primary Prostate Cancer CELL 163(4): 1011-25 (5 NOV 2015) | 1.211 |
7 | Weinreb, JC;...; Thoeny, HC; Verma, S | PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2 EUR UROL 69(1): 16-40 (JAN 2016) | 1.202 |
8 | Barbieri, CE;...; Rupp, N; Wild, PJ; Moch, H;...; Garraway, LA | Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer NAT GENET 44(6): 685-9 (JUN 2012) | 876 |
9 | James, ND;...; Thalmann, G;...; Parmar, MKB | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial LANCET 387(10024): 1163-77 (19 MAR 2016) | 863 |
10 | Balar, AV;...; Retz, MM;...; Bajorin, DF | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial LANCET 389(10064): 67-76 (7 JAN 2017) | 774 |